Addressing Manufacturing Challenges for Commercialization of iPSC-Based Therapies.

The development of reprogramming technology to generate human induced pluripotent stem cells (iPSCs) has tremendously influenced the field of regenerative medicine and clinical therapeutics where curative cell replacement therapies can be used in the treatment of devastating diseases such as Parkinson's disease (PD) and diabetes. In order to commercialize these therapies to treat a large number of individuals, it is important to demonstrate the safety and efficacy of these therapies and ensure that the manufacturing process for iPSC-derived functional cells can be industrialized at an affordable cost. However, there are a number of manufacturing obstacles that need to be addressed in order to meet this vision. It is important to note that the manufacturing process for generation of iPSC-derived specialized cells is relatively long and fairly complex and requires differentiation of high-quality iPSCs into specialized cells in a controlled manner. In this chapter, we have summarized our efforts to address the main challenges present in the industrialization of iPSC-derived cell therapy products with focus on the development of a current Good Manufacturing Practice (cGMP)-compliant iPSC manufacturing process, a comprehensive iPSC characterization platform, long-term stability of cGMP compliant iPSCs, and innovative technologies to address some of the scale-up challenges in establishment of iPSC processing in 3D computer-controlled bioreactors.

[1]  Daniel I. C. Wang,et al.  Effects of paddle impeller geometry on power input and mass transfer in small‐scale animal cell culture vessels , 1989, Biotechnology and bioengineering.

[2]  Eytan Abraham,et al.  End-to-End Platform for Human Pluripotent Stem Cell Manufacturing , 2019, International journal of molecular sciences.

[3]  James A. Thomson,et al.  Induced pluripotent stem cells from a spinal muscular atrophy patient , 2009, Nature.

[4]  Wenjun Guo,et al.  Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds , 2008, Nature Biotechnology.

[5]  Martin J. Aryee,et al.  Epigenetic memory in induced pluripotent stem cells , 2010, Nature.

[6]  George Q. Daley,et al.  Disease-Specific Induced Pluripotent Stem Cells , 2008, Cell.

[7]  R. Barrio,et al.  Generation of stable Drosophila cell lines using multicistronic vectors , 2011, Scientific reports.

[8]  A. Eresen,et al.  Natural killer cell-based adoptive transfer immunotherapy for pancreatic ductal adenocarcinoma in a KrasLSL-G12D p53LSL-R172H Pdx1-Cre mouse model. , 2019, American journal of cancer research.

[9]  Don Paul Kovarcik,et al.  A Newly Defined and Xeno-Free Culture Medium Supports Every-Other-Day Medium Replacement in the Generation and Long-Term Cultivation of Human Pluripotent Stem Cells , 2016, PloS one.

[10]  M. Butler.  Animal Cell Culture and Technology , 1997 .

[11]  Sheng Ding,et al.  Generation of rat and human induced pluripotent stem cells by combining genetic reprogramming and chemical inhibitors. , 2009, Cell stem cell.

[12]  M. Rao,et al.  Detailed Characterization of Human Induced Pluripotent Stem Cells Manufactured for Therapeutic Applications , 2016, Stem Cell Reviews and Reports.

[13]  J. Crook,et al.  Banking human induced pluripotent stem cells: lessons learned from embryonic stem cells? , 2013, Cell stem cell.

[14]  M. Rao,et al.  Alternative sources of pluripotent stem cells: scientific solutions to an ethical dilemma. , 2008, Stem cells and development.

[15]  H. Deng,et al.  Pluripotent Stem Cells Induced from Mouse Somatic Cells by Small-Molecule Compounds , 2013, Science.

[16]  Peter G Schultz,et al.  Reprogramming of murine fibroblasts to induced pluripotent stem cells with chemical complementation of Klf4 , 2009, Proceedings of the National Academy of Sciences.

[17]  Don Paul Kovarcik,et al.  cGMP-Manufactured Human Induced Pluripotent Stem Cells Are Available for Pre-clinical and Clinical Applications , 2015, Stem cell reports.

[18]  J. Rowley,et al.  Scalable Passaging of Adherent Human Pluripotent Stem Cells , 2014, PloS one.

[19]  Hidenori Akutsu,et al.  A small-molecule inhibitor of tgf-Beta signaling replaces sox2 in reprogramming by inducing nanog. , 2009, Cell stem cell.

[20]  J. Hyllner,et al.  Derivation of a Xeno‐Free Human Embryonic Stem Cell Line , 2006, Stem cells.

[21]  Isaia Sotiriadou,et al.  Human Embryonic and Induced Pluripotent Stem Cell Based Toxicity Testing Models: Future Applications in New Drug Discovery. , 2016, Current medicinal chemistry.

[22]  Amit C. Nathwani,et al.  A Systematic Evaluation of Integration Free Reprogramming Methods for Deriving Clinically Relevant Patient Specific Induced Pluripotent Stem (iPS) Cells , 2013, PloS one.

[23]  Yasuko Matsumura,et al.  A more efficient method to generate integration-free human iPS cells , 2011, Nature Methods.

[24]  M. S. Kallos,et al.  Large-scale expansion of pluripotent human embryonic stem cells in stirred-suspension bioreactors. , 2010, Tissue engineering. Part C, Methods.

[25]  Breanna S Borys,et al.  Using Computational Fluid Dynamics (CFD) Modeling to understand Murine Embryonic Stem Cell Aggregate Size and Pluripotency Distributions in Stirred Suspension Bioreactors. , 2019, Journal of biotechnology.

[26]  M. Rao.  Scalable human ES culture for therapeutic use: propagation, differentiation, genetic modification and regulatory issues , 2008, Gene Therapy.

[27]  M. Rao,et al.  Human-Induced Pluripotent Stem Cells Manufactured Using a Current Good Manufacturing Practice-Compliant Process Differentiate Into Clinically Relevant Cells From Three Germ Layers , 2018, Front. Med..

[28]  J. D. Macklis,et al.  Modeling ALS with motor neurons derived from human induced pluripotent stem cells , 2016, Nature Neuroscience.

[29]  D. Kaufman,et al.  EMBRYONIC STEM CELLS / INDUCED PLURIPOTENT STEM CELLS Concise Review : Cord Blood Banking , Transplantation and Induced Pluripotent Stem Cell : Success and Opportunities , 2011 .

[30]  A. Kurtz,et al.  Recent Trends in Research with Human Pluripotent Stem Cells: Impact of Research and Use of Cell Lines in Experimental Research and Clinical Trials , 2018, Stem cell reports.

[31]  P. Mali,et al.  Efficient human iPS cell derivation by a non-integrating plasmid from blood cells with unique epigenetic and gene expression signatures , 2011, Cell Research.

[32]  Tylor Walsh,et al.  Computational fluid dynamics modeling, a novel, and effective approach for developing scalable cell therapy manufacturing processes , 2019, Biotechnology and bioengineering.

[33]  Robert Zweigerdt,et al.  Scalable expansion of human pluripotent stem cells in suspension culture , 2011, Nature Protocols.

[34]  Vincent C. Chen,et al.  Scalable GMP compliant suspension culture system for human ES cells. , 2012, Stem cell research.

[35]  J. Takahashi.  Strategies for bringing stem cell-derived dopamine neurons to the clinic: The Kyoto trial. , 2017, Progress in brain research.

[36]  D. Ilic,et al.  Human embryonic and induced pluripotent stem cells in clinical trials. , 2015, British medical bulletin.

[37]  Christine L Mummery,et al.  Differentiation of human embryonic stem cells and induced pluripotent stem cells to cardiomyocytes: a methods overview. , 2012, Circulation research.

[38]  D. Papatsenko,et al.  Modeling Familial Cancer with Induced Pluripotent Stem Cells , 2015, Cell.

[39]  S. Nishikawa,et al.  A ROCK inhibitor permits survival of dissociated human embryonic stem cells , 2007, Nature Biotechnology.

[40]  K. Panchalingam,et al.  Long-Term Stability and Differentiation Potential of Cryopreserved cGMP-Compliant Human Induced Pluripotent Stem Cells , 2019, International journal of molecular sciences.

[41]  Shinya Yamanaka,et al.  Induced pluripotent stem cell technology: a decade of progress , 2016, Nature Reviews Drug Discovery.